AustriaAustria

12 Million Euros for Biovertis

09.10.2004

Vienna - Biovertis AG, a spin-off from Vienna-based Intercell AG, has closed a Series A financing round of up to Euro12 million. In addition, Biovertis has been awarded start-up grants and loans totalling more than Euro5 million over the next years. “We are proud that Biovertis could attract such a significant level of funding, making it one of the largest start-up financings in the last years,” said Alexander von Gabain, CEO of Intercell. The equity funding was provided by Techno Venture Management (TVM), Munich, and by Austrian Kapital & Wert Group who provided silent partnership funds. Erich Felber, co-founder and previously Executive Board member of Micromet AG, Germany, joined the company as CEO. In September 2003, Biovertis was spun-off from Intercell, a leading vaccine company, which retained a 25% equity stake post series A. Biovertis uses Intercell's AIP technology to identify and select bacterial antigens as targets.

AustriaAustria

17.03.2011

Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

AustriaAustria

06.02.2011

Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria

06.02.2011

Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...

AustriaAustria

02.02.2011

Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...

AustriaAustria

16.12.2010

Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...

AustriaAustria

04.11.2010

Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/1/article/12-million-euros-for-biovertis.html

Product of the week

Products

Events

All Events

Current issue

All issues